Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
2seventy bio
Biotech
Regeneron does 180 on 2seventy lymphoma CAR-T
Regeneron has given up on a CAR-T candidate acquired from 2seventybio last year, before it finished a phase 1/2 lymphoma study.
James Waldron
Oct 23, 2025 10:57am
Apellis COO stepping down to take first CEO job—Chutes & Ladders
Jan 17, 2025 8:30am
2seventy bio splits again, sending hemophilia A work to Novo
Jun 26, 2024 5:30pm
ASCO: Regeneron misses mark with one CR in solid tumor trial
May 23, 2024 5:00pm
Regeneron to fill gaps in obesity, break ground in cell therapy
Feb 2, 2024 10:25am
Ex-Eisai leader to be new NextPoint CEO—Chutes & Ladders
Feb 2, 2024 9:30am
